Belatacept in kidney transplant patients with systemic lupus erythematosus

OBJECTIVES: Lupus nephritis (LN) requires renal replacement therapy in 10%–30% of patients. About 30% of these patients receive a kidney transplant. Belatacept is a second-generation, selective, T-cell co-stimulator blocker (inhibits cytotoxic, T-lymphocyte antigen 4, CTLA-4) used as an alternative...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lupus Sci Med
Main Authors: Carrión-Barberà, Irene, Fajardo, Melissa, Danias, George, Tsapepas, Demetra, Gartshteyn, Yevgeniya, Fernandez, Hilda, Askanase, Anca
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Immunology and Inflammation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6928461/
https://ncbi.nlm.nih.gov/pubmed/31908816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2019-000355
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados